Silo Pharma, Inc. filed a Certificate of Change to reduce authorized common shares from 100 million to 6.67 million through a 15-for-1 reverse stock split, with fractional shares rounded up. The restructuring is a common defensive measure to maintain exchange listing compliance and improve share price perception.